Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
about
Hydroxyurea could be a good clinically relevant iron chelatorDrug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory TrialLongitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.Cardiac R2* values are independent of the image analysis approach employed.Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded RatsToward optimizing the use of deferasirox: potential benefits of combined use with deferoxamineComparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia.Reduction in mitochondrial iron alleviates cardiac damage during injuryCardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapyCost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspectiveHydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68.Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.Iron chelation therapy for transfusional iron overload: a swift evolution.Iron chelation therapy in the management of transfusion-related cardiac iron overload.MRI of cardiac iron overload.Heterogeneity of myocardial iron distribution in response to chelation therapy in patients with transfusion-dependent anemias.Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major.Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the 'Working Group on myocardial and pericardial diseases' of the European Society of Cardiology Endorsed by the Indian Academy of EchocDeferiprone for the treatment of transfusional iron overload in thalassemia.Current recommendations for chelation for transfusion-dependent thalassemia.Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major.Chelation therapy in cardiovascular disease: an update.Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach.Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia majorDeferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants.In search of the optimal iron chelation therapy for patients with thalassemia major.Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice.Detection of myocardial iron overload by two-dimensional speckle tracking in patients with beta-thalassaemia major: a combined echocardiographic and T2* segmental CMR study.A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.Orphan Drugs and Potential Novel Approaches for Therapies of β-Thalassemia: Current Status and Future ExpectationsManagement of cardiac hemochromatosis.
P2860
Q28536619-F7C2F56A-EF9B-4007-A744-F6BD8ED42566Q28552171-FF0BA0C8-864C-4FFD-8763-F5D4FCBACA87Q33647638-683E0E9F-B75C-4D9A-B5C7-35DB7502BEAFQ34940609-6A44A297-6E29-4635-86F8-9157DC5C0D23Q35296244-18FA1D92-D75E-4F98-ADCC-5F6102531E25Q36080315-5FD5F301-C71A-49F3-A416-A616C19EC7B8Q36498403-BFED5F86-F838-4559-8C5C-03C171F7AF1EQ36500199-153CE7FD-003B-40B2-93B8-CEC4C64F940FQ36636071-B46B225D-2F64-40E2-A2BD-27331C6F8509Q36690349-141BEE3E-541F-4CFD-8336-7760453294C0Q37132320-F555166D-08E9-46A8-9678-72F6AD2460AAQ37631557-0AB755F3-3284-45C0-9BF2-B202FFB885DCQ37695691-D5FADB33-C3BA-416F-BEC6-66EF7A155570Q37930656-821AB707-E641-4D4B-AD82-C78A83592873Q37992181-238B8B2B-A66D-43A8-933B-BD22658FD897Q38054638-11A4038C-A3BF-45CB-92FA-16FAD02CE958Q38111682-2DB13A43-102F-413C-9F80-35C434755E46Q38258076-4F4CAB17-D890-4AE7-B421-34FD4640289DQ38782767-03A8FF4A-448B-4E58-B0E1-DFAD5AE74761Q38817259-7135BE87-7B22-4516-975C-11695D6CFC02Q38836184-3AE69B17-C28B-4A97-8A82-9E60635A4AC2Q38931755-C3F70BF0-FF44-4E9C-AED1-82A9E9EB18F8Q38968558-6623B76C-DF68-4CDF-8018-E7EBA913E8E5Q38990649-8E83D85D-498D-4D15-AE92-C1D3E7A5DA04Q39361634-B8E6D2FF-B9AF-48CE-8FCE-1C8A73138A16Q40334850-F869047F-E52E-4381-9148-1FBE6056AAE4Q41857841-809D1019-C112-4D31-8588-5AA9FD62E99EQ42183463-F5A1ACCC-2DF5-40D0-A7FF-5952D3B7907CQ42240759-A20D0AE2-4D3B-4DF4-955C-98B190822329Q42558429-496E59F8-9B59-4BAF-8E34-ABF26080B0FDQ42601757-24340EBC-DBA2-4B21-BED9-82DF59DC6978Q46460675-4EA516A3-4D96-478C-AA99-D5C1775D3AFBQ47931907-B5456809-43BE-448E-BA11-AA4C823542ECQ48539935-CC697031-4071-4928-BB51-CA55F20F3855Q48665941-5EA4C982-6E34-48A1-8CDA-F2E13FEDC9ECQ51877530-C835B567-4843-4131-99DF-6984B5254231Q52575650-F2851DC8-8A72-4607-B2C6-7EDDFF0828F5Q53153270-B07DB4B4-4B01-4CC7-A59B-E5C70818F084Q54585888-68A2B7EE-A71B-4FE5-A7A0-985DA3F148B0Q55230811-6CA062E6-4146-40E1-B8A6-1178C6CAF442
P2860
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@ast
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@en
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@nl
type
label
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@ast
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@en
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@nl
prefLabel
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@ast
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@en
Deferasirox, deferiprone and d ...... ve magnetic resonance imaging.
@nl
P2093
P2860
P1433
P1476
Deferasirox, deferiprone and d ...... ive magnetic resonance imaging
@en
P2093
Aldo Filosa
Alessia Pepe
Alma Lippi
Antonella Meloni
Antonella Quarta
Cristina Malaventura
Giuseppe Rossi
Lorella Pitrolo
Luciano Prossomariti
Marcello Capra
P2860
P356
10.3324/HAEMATOL.2009.019042
P577
2010-09-30T00:00:00Z